At a glance
ClinicalIndex Comparison Record- ✓Tumor lesion(s) accessible for safe histological biopsy
- ✓Measurable disease by RECIST v1.1
- ✓Enrollment in GE-269-001 CD8 imaging trial with available slots
- ✓Age ≥18 years
- ✕Signs or symptoms of infection within 2 weeks prior to treatment
- ✕Prior checkpoint inhibitor treatment (cohorts 1, 2, 4)
- ✕History of severe allergic or hypersensitivity reactions to chimeric or humanized antibodies
- ✕Pregnancy or lactation
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT05483400Phase 2RecruitingUpdate OverdueUpdated 15mo ago · Completion was 9mo agoOpen Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors: TIRACAN
In Brief
A Phase 2 clinical trial evaluating Tiragolumab and atezolizumab for Head and Neck Neoplasms and 2 related conditions. Currently recruiting, targeting 97 participants across 1 site.
Signals
Detailed Summary
In this open label phase II trial combination therapy with the anti-PD-L1 antibody atezolizumab and the anti-TIGIT antibody tiragolumab will be investigated in patients with localized HNSCC who will undergo surgery, advanced or metastatic MSI-H cancer, PD-1 resistant metastatic melanoma, and patients with a locally advanced or metastatic solid tumor who, in the opinion of the investigator, based on available clinical data, may benefit from treatment with anti-PD-L1 and anti-TIGIT immunotherapy.
Study Details
Timeline
Interventions
three weekly tiragolumab 1200 mg intravenous plus tiragolumab 600 mg intravenous.